14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
OBIO vs PYPD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (31.1/100 SELL vs. 42.9/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $7.02 (N/M Forward P/E, -195.4% operating margin) versus PYPD at $6.50 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While OBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -195.4% operating margin) and revenue trajectory (+0.0% vs. -89.4% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OBIO vs PYPD. Trailing 12-month operating profitability (OBIO -195.4% vs PYPD 0.0%) and valuation multiples (OBIO N/M vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ OBIO vs PYPD Key Questions & Quantitative Answers
As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (31.1/100 SELL vs. 42.9/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $7.02 (N/M Forward P/E, -195.4% operating margin) versus PYPD at $6.50 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While OBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -195.4% operating margin) and revenue trajectory (+0.0% vs. -89.4% YoY).
OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with PYPD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, OBIO generates $31M in USD-normalized revenue versus N/A for PYPD. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PYPD.
OBIO screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin), whereas PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus PYPD (-243.6% ROE) capital efficiency.
In options market volatility and institutional positioning, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 80% Vol realized risk). By comparison, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.88β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.